Gilead Sciences stock gains on Q2 revenue beat
Published on 08/24/2026 at 09:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences (ISIN US3755581036) is trading against a fresh earnings backdrop after reporting $7.80 billion in revenue for Q2 2026 and a loss of $6.75 per share, while the shares opened at $146.12 with a market value of $181.18 billion on August 23, 2026. The quarter also showed a sharp split between growth and profitability, with product sales excluding Veklury up 10% to $7.6 billion.
That mix matters because the core franchise is still doing the work. HIV product sales rose 12% to $5.7 billion, Biktarvy reached $3.8 billion, and Descovy climbed 48% to $967 million in the same quarter.
Core sales lead the quarter
For investors, the most useful comparison is the top line versus the bottom line. Revenue of $7.80 billion beat the $7.40 billion consensus cited in market coverage, yet the quarter also included $11.2 billion in acquired in-process R&D expenses that pushed GAAP earnings to a loss.
Several operating lines stayed strong even as the acquisition charge dominated the income statement. Liver-disease revenue increased 10% to $877 million, Trodelvy sales rose 26% to $457 million, and Yeztugo generated $232 million as the launch advanced.
What the numbers say
The pattern is clear: Gilead's commercial portfolio improved faster than its reported profit profile. The result was a quarter with $7.80 billion in revenue, $7.6 billion in product sales excluding Veklury, and $5.7 billion from HIV products, all inside the same reporting period.
Market data adds another layer. The stock opened at $146.12, and its 52-week range runs from $108.46 to $157.29, which leaves the shares much closer to the upper end of that band than the lower end.
Yeztugo adds scale
Yeztugo is Gilead's twice-yearly injectable HIV-prevention medicine, and its $232 million contribution in Q2 2026 shows that new launches are adding to the franchise beyond Biktarvy and Descovy. That matters because the quarter's growth was not driven by one product alone.
Price and trading range
As of August 23, 2026, Gilead Sciences stock was trading at $146.12. The company also carried a market capitalization of $181.18 billion, with the shares sitting within a 52-week range of $108.46 to $157.29.
More on Gilead Sciences
Gilead Sciences is a biopharmaceutical company built around HIV, liver disease, and oncology, with Biktarvy, Descovy, Trodelvy, and Yeztugo representing key commercial products in the latest quarter.
Gilead Sciences stock at a glance
Company: Gilead Sciences, Inc.
ISIN: US3755581036
Ticker: GILD
Exchange: Nasdaq
Price (as of August 23, 2026, 4:00 p.m. ET): $146.12 USD
Market cap: $181.18 billion (as of August 23, 2026)
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq-100
